Sustiva (efavirenz) label was recently revised

The Sustiva (efavirenz) label was recently revised. The following sections in the Prescribing Information and Patient Counseling Information were update to include information about catatonia.  WARNINGS AND PRECAUTIONS subsection 5.5 Psychiatric Symptoms  ADVERSE REACTIONS subsection 6.2 Postmarketing Experience  The updated label will soon be available drugs@fda or DailyMed

Steve Morin Office of Health and Constituent Affairs Food and Drug Administration Richard Klein Office of Health and Constituent Affairs Food and Drug Administration Kimberly Struble Division of Antiviral Products Food and Drug Administration